Co-Administration of 5α-Reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids

    Nantia Othonos, Thomas Marjot, Conor Woods … Jeremy W. Tomlinson
    Studysummary This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Incidence of Type 2 Diabetes Mellitus in Men Receiving Steroid 5α-Reductase Inhibitors: Population-Based Cohort Study BMJ. British medical journal · 2019
    2. Long-Term Dutasteride Therapy in Men with Benign Prostatic Hyperplasia Alters Glucose and Lipid Profiles and Increases Severity of Erectile Dysfunction Hormone Molecular Biology and Clinical Investigation · 2017
    3. 5α-Reductase Type 1 Deficiency or Inhibition Predisposes to Insulin Resistance, Hepatic Steatosis, and Liver Fibrosis in Rodents Diabetes · 2014
    4. 5α-Reduced Glucocorticoids: A Story of Natural Selection Journal of Endocrinology · 2011